Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Trimetazidine dihydrochloride
Cat. No.:
OB0225LY-0024
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Trimetazidine dihydrochloride is a small molecule compound improves myocardial glucose utilization by inhibiting fatty acid metabolism.
Synonym:
Yoshimilon; Kyurinett; Vastarel F; 13171-25-0; 1-(2,3,4-Trimethoxybenzyl)piperazine; 1-[(2,3,4-Trimethoxyphenyl)methyl]piperazine; 1-(2,3,4-Trimethoxy-benzyl)-piperazine; 1-(2,3,4-Trimethoxybenzyl)piperazine, hydrochloride
CAS No.:
13171-25-0
Compound CID:
21109
Formula:
C14H24Cl2N2O3
Formula Weight:
339.258
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Trimetazidine dihydrochloride can be used to study energy metabolism in cardiomyocytes.
Library Information
Targets:
Metabolic enzymes
Receptors:
Mitochondrial long-chain 3-ketoacyl thiolase
Pathways:
Autophagy; Metabolism
Plate Number:
AOCL-1
Plate Location:
c5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
65 mg/mL; 191.59 mM
